Invivyd (IVVD) Competitors $0.63 -0.01 (-0.82%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. RNAC, TSVT, MNPR, SEPN, MBX, AQST, ITOS, CMPX, AVIR, and TERNShould you be buying Invivyd stock or one of its competitors? The main competitors of Invivyd include Cartesian Therapeutics (RNAC), 2seventy bio (TSVT), Monopar Therapeutics (MNPR), Septerna (SEPN), MBX Biosciences (MBX), Aquestive Therapeutics (AQST), iTeos Therapeutics (ITOS), Compass Therapeutics (CMPX), Atea Pharmaceuticals (AVIR), and Terns Pharmaceuticals (TERN). These companies are all part of the "pharmaceutical products" industry. Invivyd vs. Cartesian Therapeutics 2seventy bio Monopar Therapeutics Septerna MBX Biosciences Aquestive Therapeutics iTeos Therapeutics Compass Therapeutics Atea Pharmaceuticals Terns Pharmaceuticals Invivyd (NASDAQ:IVVD) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations. Does the MarketBeat Community favor IVVD or RNAC? Cartesian Therapeutics received 14 more outperform votes than Invivyd when rated by MarketBeat users. Likewise, 95.00% of users gave Cartesian Therapeutics an outperform vote while only 85.71% of users gave Invivyd an outperform vote. CompanyUnderperformOutperformInvivydOutperform Votes2485.71% Underperform Votes414.29%Cartesian TherapeuticsOutperform Votes3895.00% Underperform Votes25.00% Which has better valuation & earnings, IVVD or RNAC? Invivyd has higher earnings, but lower revenue than Cartesian Therapeutics. Invivyd is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$25.38M2.98-$198.64M-$1.44-0.44Cartesian Therapeutics$38.91M7.99-$219.71M-$52.83-0.23 Do analysts rate IVVD or RNAC? Invivyd currently has a consensus price target of $7.52, indicating a potential upside of 1,092.74%. Cartesian Therapeutics has a consensus price target of $42.67, indicating a potential upside of 255.56%. Given Invivyd's stronger consensus rating and higher probable upside, equities analysts plainly believe Invivyd is more favorable than Cartesian Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Cartesian Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is IVVD or RNAC more profitable? Invivyd has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets InvivydN/A -155.33% -114.88% Cartesian Therapeutics -510.72%N/A -6.03% Does the media prefer IVVD or RNAC? In the previous week, Cartesian Therapeutics had 3 more articles in the media than Invivyd. MarketBeat recorded 5 mentions for Cartesian Therapeutics and 2 mentions for Invivyd. Invivyd's average media sentiment score of 1.43 beat Cartesian Therapeutics' score of 0.98 indicating that Invivyd is being referred to more favorably in the media. Company Overall Sentiment Invivyd Positive Cartesian Therapeutics Positive Do institutionals & insiders believe in IVVD or RNAC? 70.4% of Invivyd shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 25.4% of Invivyd shares are owned by insiders. Comparatively, 57.9% of Cartesian Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has more volatility and risk, IVVD or RNAC? Invivyd has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. SummaryCartesian Therapeutics beats Invivyd on 12 of the 19 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition Export to ExcelMetricInvivydBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.60M$3.00B$5.57B$7.82BDividend YieldN/A1.89%5.11%4.22%P/E Ratio-0.3230.4222.4218.48Price / Sales2.98498.92394.10103.91Price / CashN/A168.6838.1834.62Price / Book0.393.206.774.25Net Income-$198.64M-$72.35M$3.22B$248.23M7 Day Performance-2.19%3.57%3.25%3.29%1 Month Performance5.03%0.17%0.01%2.42%1 Year Performance-71.61%-21.21%18.00%5.54% Invivyd Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd3.6207 of 5 stars$0.63-0.8%$7.52+1,092.7%-71.6%$76.22M$25.38M-0.32100Upcoming EarningsShort Interest ↓Positive NewsGap DownRNACCartesian Therapeutics1.9551 of 5 stars$10.34-1.5%$42.14+307.6%-45.6%$267.88M$38.91M-0.2064Upcoming EarningsGap DownTSVT2seventy bio1.7351 of 5 stars$4.99+0.2%$5.60+12.2%+9.4%$261.17M$37.86M-2.68440Short Interest ↑News CoverageMNPRMonopar Therapeutics3.0979 of 5 stars$42.71+7.9%$55.33+29.6%+1,167.1%$261.09MN/A-21.6810Upcoming EarningsNews CoveragePositive NewsGap DownSEPNSepterna2.2586 of 5 stars$5.87-0.5%$33.00+462.2%N/A$260.88M$1.08M0.00N/ANews CoveragePositive NewsMBXMBX Biosciences2.4915 of 5 stars$7.64+0.3%$37.50+390.8%N/A$255.36MN/A0.0036AQSTAquestive Therapeutics1.5117 of 5 stars$2.58+2.8%$10.67+313.4%-13.1%$255.09M$57.56M-5.73160Upcoming EarningsITOSiTeos Therapeutics2.0927 of 5 stars$6.62+1.7%$25.75+289.0%-32.5%$252.84M$35M-2.1090Earnings ReportAnalyst ForecastNews CoverageCMPXCompass Therapeutics3.3928 of 5 stars$1.78+1.7%$13.38+651.4%+29.2%$246.14M$850,000.00-4.8120Analyst ForecastShort Interest ↑AVIRAtea Pharmaceuticals3.1159 of 5 stars$2.86-3.7%$6.00+109.8%-20.3%$244.60MN/A-1.3870TERNTerns Pharmaceuticals4.2642 of 5 stars$2.71+12.9%$18.38+578.0%-34.7%$236.58MN/A-2.3040Positive News Related Companies and Tools Related Companies RNAC Competitors TSVT Competitors MNPR Competitors SEPN Competitors MBX Competitors AQST Competitors ITOS Competitors CMPX Competitors AVIR Competitors TERN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IVVD Stock Free IVVD Stock Alerts